• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advanced Functional Materials >Tumor Acidity and Near-Infrared Light Responsive Dual Drug Delivery Polydopamine-Based Nanoparticles for Chemo-Photothermal Therapy
【24h】

Tumor Acidity and Near-Infrared Light Responsive Dual Drug Delivery Polydopamine-Based Nanoparticles for Chemo-Photothermal Therapy

机译：肿瘤酸度和近红外光响应性双药物递送聚二胺基纳米粒子进行化学光热疗法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Photothermal therapy (PTT) combined with chemotherapy, a promising strategy for breast cancer treatment, has a high potential to control drug release, reduce multidrug resistance, and improve therapeutic efficacy. The challenge is how to realize tumor ablation in deeper tissue and NIR-controlled drug delivery. Herein, tumor acidity and near-infrared light (NIR) responsive folic acid (FA) functionalized polydopamine (DPA) nanoparticles (NPs) are developed for doxorubicin (DOX) and epigallocatechin-3-gallate (EGCG) dual delivery. With the assistance of NIR, the cellular uptake of DOX-EGCG/DPA-FA NPs is about three- to sixfold higher when compared with the free DOX group and the control group without NIR irradiation. Moreover, biodistribution study in vivo indicates that DPA-FA NPs can enhance tumoral accumulation, penetration, retention of drugs, and display a approximate to 4- and 19-fold higher intra-tumoral distribution than that of the DPA NPs and free drug groups at 24 h postinjection. Furthermore, 60% of breast cancer-bearing mice survive over 70 days in the DOX-EGCG/DPA-FA NPs group. Additionally, DOX-EGCG/DPA-FA NPs can effectively boost therapeutic efficacy by inducing significant suppression of tumor growth and angiogenesis, and enhancement of apoptosis and necrosis of breast cancer cells. Taken together, DOX-EGCG/DPA-FA NPs may have potential applications as a useful nanoscale vector for enhanced cancer therapy.
机译：光热疗（PTT）联合化疗，乳腺癌治疗的有希望的策略，对药物释放有很大的潜力，降低多药耐药性，提高治疗效果。挑战是如何在更深的组织和NIR控制的药物递送中实现肿瘤消融。本文，肿瘤酸度和近红外光（NIR）响应叶酸（FA）官能化的聚德胺（DPA）纳米颗粒（DPA）用于多柔比星（DOX）和EPIGALLOCATECHIN-3-Gallate（EGCG）双重递送。在NIR的帮助下，与无鼻辐射的无鼻辐射相比，DOX-EGCG / DPA-FA NPS的细胞摄取约为3至六倍。此外，体内生物分布研究表明DPA-FA NPS可以增强肿瘤积累，渗透，药物保留，并显示比DPA NPS和游离药物群体更高的肿瘤内肿瘤内的4-19倍和19倍。 24小时假释。此外，60％的乳腺癌小鼠在DOX-EGCG / DPA-FA NPS组中存活超过70天。此外，DOX-EGCG / DPA-FA NPS可以通过诱导显着抑制肿瘤生长和血管生成的显着抑制，增强凋亡和乳腺癌细胞坏死的增强和乳腺癌细胞的凋亡和坏死的能力来有效地提高治疗效果。携带在一起，DOX-EGCG / DPA-FA NPS可能具有潜在的应用作为增强癌症治疗的有用纳米级载体。

著录项

  • 来源
    《Advanced Functional Materials》 |2021年第18期|2009733.1-2009733.12|共12页
  • 作者

    Fan Rangrang; Chen Caili; Hou Huan; Chuan Di; Mu Min; Liu Zhiyong; Liang Ruichao; Guo Gang; Xu Jianguo;

  • 作者单位

    Sichuan Univ West China Hosp Dept Neurosurg Chengdu 610041 Peoples R China|Sichuan Univ West China Hosp State Key Lab Biotherapy & Canc Ctr Chengdu 610041 Peoples R China|Collaborat Innovat Ctr Biotherapy Chengdu 610041 Peoples R China;

    Xinxiang Med Univ Sch Basic Med Sci Xinxiang 453003 Henan Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy & Canc Ctr Chengdu 610041 Peoples R China|Collaborat Innovat Ctr Biotherapy Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy & Canc Ctr Chengdu 610041 Peoples R China|Collaborat Innovat Ctr Biotherapy Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy & Canc Ctr Chengdu 610041 Peoples R China|Collaborat Innovat Ctr Biotherapy Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp Dept Neurosurg Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp Dept Neurosurg Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy & Canc Ctr Chengdu 610041 Peoples R China|Collaborat Innovat Ctr Biotherapy Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp Dept Neurosurg Chengdu 610041 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    acid#8208; responsive drug delivery; chemo#8208; photothermal therapy; dual drug delivery; NIR#8208; responsive drug delivery; polydopamine;

    机译：酸性响应药物递送;化学光热疗法;双重药物递送;NIR响应药物递送;聚二胺;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号